fatty liver disease
Study suggests phospholipid therapy may impact fatty liver disease outcomes
April 29, 2026Research and Development fatty liver disease, phospholipid therapy
A randomised clinical trial has reported that treatment with essential phospholipids (Essentiale) may reduce liver fat and improve symptoms in …
FDA approves first treatment for liver scarring due to fatty liver disease
March 15, 2024Medical Communications Endocrinology, FDA, fatty liver disease, liver scarring, nash
The US Food and Drug Administration (FDA) has announced that it has approved Rezdiffra (resmetirom) for the treatment of adult …
Gilead shares drop 4% after failure of NASH drug to meet primary endpoint
February 12, 2019Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib
Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …
Gilead’s drug boosted by positive Phase II trials and aims to move forward
October 21, 2016Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease
Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
